A secretome screen in primary human lung fibroblasts identifies FGF9 as a novel regulator of cellular senescence
Year: 2025
Type: article
Abstract: Senescent cells contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF), a disease with significant unmet need and therefore, there is an interest in discovering new drug targets that regulate this process. We design and perform a phenotypic screen with a secreted protein library in primary human lung fibroblasts to identify modulators of cell senescence. We identify FGF9 as a suppressor of several senescence phenotypes reducing stimulated p21 expression, enlarged morphology, DNA damage and SASP secretion, which is consistent with both DNA-damage and ROS induced senescence. We also show that FGF9 reduces fibroblast activation in both healthy and IPF fibroblasts shown by a reduction in pro-fibrotic markers such as α-smooth muscle actin and COL1A1 mRNA. Our findings identify FGF9 as a suppressor of both senescence and fibrotic features in lung fibroblasts and therefore could be targeted as a new therapeutic strategy for respiratory diseases such as IPF.
Source: SLAS DISCOVERY
Authors: Jenna Bradley, Patrick O'Shea, Catherine Wrench, Johan Mattsson, Roxane Paulin, Catherine Overed-Sayer, Laura Rosenberg, Henric Olsson, Davide Gianni
Institutions: AstraZeneca (United Kingdom), AstraZeneca (Sweden)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,070
OpenAlex ID: W4408051653
